B

Bicara Therapeutics Inc
NASDAQ:BCAX

Watchlist Manager
Bicara Therapeutics Inc
NASDAQ:BCAX
Watchlist
Price: 11.11 USD -4.22%
Market Cap: 605.9m USD

Intrinsic Value

The intrinsic value of one BCAX stock under the Base Case scenario is 8.98 USD. Compared to the current market price of 11.11 USD, Bicara Therapeutics Inc is Overvalued by 19%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BCAX Intrinsic Value
8.98 USD
Overvaluation 19%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation History
Bicara Therapeutics Inc

What is Valuation History?
Compare BCAX to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BCAX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Bicara Therapeutics Inc
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Bicara Therapeutics Inc

Balance Sheet Decomposition
Bicara Therapeutics Inc

Current Assets 470.8m
Cash & Short-Term Investments 462.1m
Other Current Assets 8.7m
Non-Current Assets 7.3m
PP&E 688k
Other Non-Current Assets 6.6m
Efficiency

Free Cash Flow Analysis
Bicara Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Bicara Therapeutics Inc

Revenue
0 USD
Operating Expenses
-124.2m USD
Operating Income
-124.2m USD
Other Expenses
19.3m USD
Net Income
-104.8m USD
Fundamental Scores

BCAX Profitability Score
Profitability Due Diligence

Bicara Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Negative ROE
26/100
Profitability
Score

Bicara Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

BCAX Solvency Score
Solvency Due Diligence

Bicara Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Bicara Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCAX Price Targets Summary
Bicara Therapeutics Inc

Wall Street analysts forecast BCAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCAX is 33.25 USD with a low forecast of 8.08 USD and a high forecast of 50.4 USD.

Lowest
Price Target
8.08 USD
27% Downside
Average
Price Target
33.25 USD
199% Upside
Highest
Price Target
50.4 USD
354% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Bicara Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BCAX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BCAX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one BCAX stock?

The intrinsic value of one BCAX stock under the Base Case scenario is 8.98 USD.

Is BCAX stock undervalued or overvalued?

Compared to the current market price of 11.11 USD, Bicara Therapeutics Inc is Overvalued by 19%.

Back to Top